Pharmaceutical Executive-07-01-2010

In France, it took a president's keynote speech to underscore the government's new understanding that there is more to pharmaceuticals than cost-containment

Focus Reports discusses kep questions regarding France's pharma industry

FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.

As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.

Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.

Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.

Once occupied by a single pharma leader, the roles of CEO, president, and board chairman are increasingly being separated. What's behind the trend?

Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?